We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.ContinueLearn More X
Phillips-Medisize will exhibit at the Drug Delivery to the Lungs Conference, which is taking place at Edinburgh International Conference Center on 6-8 December 2017.
DDL is Europe’s premier conference and exhibition dedicated to pulmonary and nasal drug delivery. Treating and monitoring chronic respiratory diseases such as asthma, where patients can self-administer today with established dry powder inhalers (DPIs) and metered dose inhalers (MHIs), as well as more recent soft mist inhalers (SMIs) is another theme during DDL.
As the development partner of the first DPI, and being involved in the development of various inhaler programmes, Phillips-Medisize has been at the forefront of inhalation technology for over 30 years. The company’s experience spans the entire system, from feasibility to selecting the right components – through to commercial scale production including electronics integration.
Devices for connected health solutions where respiratory devices, connected services and drugs are completely integrated are also a theme at Phillips-Medisize’s exhibition stand. Visitors can discuss how getting better therapeutic results in the respiratory field can be achieved by superior devices and improved patient engagement.
Bill Welch, chief technology officer Phillips-Medisize remarked, "We continue to be very focused on partnerships built on innovation, as well as our continuum of contract services for digital interfaces to maximise the patient and caregiver experience. With the acquisition by Molex, we also vertically integrating electronics into our existing capabilities on respiratory devices."